文献速递甲状腺疾病

妊娠期左甲状腺素使用的知识、态度、信念与治疗负担

Knowledge, Attitudes, Beliefs, and Treatment Burden Related to the Use of Levothyroxine in Hypothyroid Pregnant Women in the United States.
PubMed 文献 · Thyroid · 2021-01-19

约三分之一孕妇对甲状腺功能减退诊断感到不安或焦虑,45%报告未获医生关于未控制甲减母婴风险或充分控制获益的解释,三分之二患者表达LT4相关治疗负担的担忧。结论支持需加强有效沟通和个体化咨询。

要点

  • 约三分之一使用LT4的孕妇对甲减诊断感到不安或焦虑。
  • 45%的孕妇未获医生关于未控制甲减母婴风险或LT4获益的解释。
  • 三分之二患者表达LT4相关治疗负担的担忧,需个体化咨询。

核心结论

  • 使用LT4的孕妇存在对甲减诊断的不安和LT4治疗负担的担忧,且近半数未获充分风险获益解释。
  • 需加强有效沟通和个体化咨询以解决恐惧、焦虑和不确定性,促进依从性并减少不良母婴结局。

研究设计与样本

  • 横断面研究,调查2019年1月1日至12月31日在美国某三级学术医疗中心接受LT4治疗的孕妇。
  • 匿名在线调查收集人口学数据及关于LT4获益风险、知识、信念、态度和负担的多选题。

主要发现

  • 62%的孕妇在妊娠前超过12个月诊断为甲减,16%在妊娠前不足或约12个月诊断,22%在妊娠期诊断。
  • 约三分之一使用LT4的孕妇因甲减诊断感到不安或焦虑。
  • 45%的受访者报告未获医生关于未控制甲减母婴风险或充分控制获益的解释。
  • 三分之二患者表达各种LT4相关治疗负担的担忧。

临床怎么用

  • 对LT4治疗获益明确的孕妇,有效沟通和个体化咨询可帮助克服担忧、促进依从性并减少不良母婴结局。
  • 对获益不明确的孕妇,临床医生应意识到LT4相关治疗负担并实施以患者为中心的方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The use of prescribed medications during pregnancy is a challenge and an underestimated source of treatment burden. Levothyroxine (LT4) for the treatment of overt and subclinical hypothyroidism is extensively prescribed during pregnancy. To this end, we aimed to explore the patients' perceived benefits and risks, knowledge, beliefs, attitudes, and related burden of LT4 therapy during pregnancy. Methods: In this cross-sectional study, we surveyed pregnant women who were treated with LT4 during pregnancy from January 1, 2019, to December 31, 2019, in a tertiary academic medical center of the United States. The anonymous online survey included questions to gather demographic data and multiple-choice questions regarding the benefits and risks, knowledge, beliefs, attitudes, and burden related to LT4 use during pregnancy. Results: Sixty-four pregnant women (mean age 31.5 years) completed the study survey (response rate: 96%): 62% were diagnosed with hypothyroidism more than 12 months before pregnancy, 16% less than or about 12 months before pregnancy, and 22% during pregnancy. We found that one-third of pregnant women using LT4 had a feeling of uneasiness/anxiety due to their hypothyroidism diagnosis. About half of the respondents (45%) reported that they did not receive an explanation by their clinician regarding the maternal/fetal risks of uncontrolled hypothyroidism or the benefits of adequate control. Finally, two in three patients expressed various concerns of LT4-related treatment burden. Conclusions: Our findings support the need for increased effective communication and tailored counseling to address fears, anxiety, and uncertainties about the benefits and risks of LT4 use in pregnancy. For patients with clear benefits from LT4 treatment in pregnancy, it could help to overcome their concerns, promote adherence, and decrease adverse maternal/fetal outcomes. For patients with no clear benefits established, clinicians need to be aware of LT4-related treatment burden in pregnancy and implement patient-centered approaches in their clinical practices.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Toloza FJK, Theriot SE, Singh Ospina NM, et al. Knowledge, Attitudes, Beliefs, and Treatment Burden Related to the Use of Levothyroxine in Hypothyroid Pregnant Women in the United States. Thyroid. 2021. PMID: 33176609. doi:10.1089/thy.2020.0629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。